Clinical Trial Update: Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency [Phase 2]

View source ↗

Summary

Oral TheraCLEC is being studied in cystic fibrosis patients with exocrine pancreatic insufficiency in a Phase 2 trial. The study status is listed as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Pancreatic Insufficiency

Drugs mentioned

• Oral TheraCLEC

Snippet

Sponsor: Anthera Pharmaceuticals | Conditions: Cystic Fibrosis, Pancreatic Insufficiency | Phase 2 | Status: COMPLETED